Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12901280 | 0.89 | MAPT (0.38) | KMT2AALDH1A1SOS1MITF | |
| SCHEMBL1228711 | 0.88 | KCNH2 (0.45) | KMT2AALDH1A1SOS1KCNH2 | |
| SCHEMBL1228815 | 0.86 | MEN1 (0.39) | KMT2A | |
| SCHEMBL1228662 | 0.85 | KMT2A (0.34) | KMT2AALDH1A1SOS1MITFPKM | |
| SCHEMBL13279504 | 0.80 | MAPT (0.51) | KMT2AALDH1A1 | |
| SCHEMBL1228592 | 0.79 | ALDH1A1 (0.35) | KMT2AALDH1A1SOS1MITFPKM | |
| SCHEMBL13281397 | 0.75 | PTGS1 (0.45) | KCNH2 | |
| SCHEMBL13281672 | 0.75 | PTGS1 (0.44) | KCNH2 | |
| SCHEMBL1228697 | 0.74 | ACHE (0.40) | ALDH1A1PKM | |
| SCHEMBL5536388 | 0.70 | ALDH1A1 (0.43) | KMT2AALDH1A1SOS1MITFPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459570-B1 | NITROIMIDAZOOXAZINE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | KMT2A 1440/4885ALDH1A1 2444/4885SOS1 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.